Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report issued on Sunday. The firm set a “sell” rating on the basic materials company’s stock.

Arcadia Biosciences Trading Down 4.5 %

RKDA opened at $3.15 on Friday. The stock has a market cap of $4.30 million, a price-to-earnings ratio of -0.74 and a beta of 0.86. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $10.31. The stock has a fifty day moving average price of $4.33 and a 200 day moving average price of $4.11.

Institutional Trading of Arcadia Biosciences

A hedge fund recently bought a new stake in Arcadia Biosciences stock. Geode Capital Management LLC purchased a new position in Arcadia Biosciences, Inc. (NASDAQ:RKDA) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned about 0.90% of Arcadia Biosciences at the end of the most recent reporting period. 17.73% of the stock is currently owned by hedge funds and other institutional investors.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.